Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Clinical Oncology

• Publication date

  2016-09-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2015.63.4691PMID 26976423
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.

  2015cited by this paper
• A randomized trial of bevacizumab for newly diagnosed glioblastoma.

  2014cited by this paper
• Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

  2014cited by this paper
• Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

  2014cited by this paper
• Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation.

  2013cited by this paper
• Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure

  2012cited by this paper
• Longitudinal Data with Follow-up Truncated by Death: Match the Analysis Method to Research Aims.

  2010cited by this paper
• Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

  2009cited by this paper
• Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

  2009cited by this paper
• Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

  2009cited by this paper
• Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.

  2008cited by this paper
• Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

  2007cited by this paper
• Estimating treatment effects in randomized trials with treatment switching.

  2006cited by this paper
• Estimating treatment effects in randomized trials with treatment switching

  2006cited by this paper
• A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

  2006cited by this paper
• MGMT gene silencing and benefit from temozolomide in glioblastoma.

  2005cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• Uses and limitations of randomization-based efficacy estimators

  2005cited by this paper
• The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires

  1996cited by this paper
• Adaptive biased urn randomization in small strata when blinding is impossible.

  1995cited by this paper
• Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms.

  1993cited by this paper
• Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo

  1992cited by this paper
• Correcting for non-compliance in randomized trials using rank preserving structural failure time models

  1991cited by this paper
• Response criteria for phase II studies of supratentorial malignant glioma.

  1990cited by this paper
• A simple approximation for calculating sample sizes for comparing independent proportions.

  1980cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper

• Comprehensive analysis reveals cholesterol metabolism-related signature for predicting prognosis and guiding individualized treatment of glioma

  2025cites this paper
• Updated Clinical practice guidelines for the management of adult diffuse gliomas.

  2025cites this paper
• Prickle4 Drives Microenvironmental Remodeling and Resistance to Parp Inhibition in IDH‐Mutant Glioma

  2025cites this paper
• Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial

  2025cites this paper
• Temozolomide-Derived Therapeutic Strategies to Overcome Resistance in Glioblastoma.

  2025cites this paper
• The Pivotal Role of NF-κB in Glioblastoma: Mechanisms of Activation and Therapeutic Implications

  2025cites this paper
• The Evidence That Brain Cancers Could Be Effectively Treated with In-Home Radiofrequency Waves

  2025cites this paper
• Predictive role of MGMT and IDH status in the efficacy of bevacizumab for high-grade glioma: a retrospective study

  2025cites this paper
• Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions.

  2025cites this paper
• Reirradiation of recurrent glioblastoma: Results from a single-center retrospective cohort study

  2025cites this paper
• The Adverse Effects and Use of Bevacizumab in Patients with Glioblastoma: A Systematic Review and Meta-Analysis

  2025cites this paper
• Survivin Interference and SurVaxM as an Adjunct Therapy for Glioblastoma Multiforme

  2025cites this paper
• Treatment mechanism and research progress of bevacizumab for glioblastoma.

  2025cites this paper
• Lipid nanoparticles for treatment of glioblastoma multiforme: current status of research and clinical translation

  2025cites this paper
• A systematic review of immunotherapies in combination with temozolomide as treatment for glioblastoma.

  2025cites this paper
• Identification of inflammation-related genes signature to establish a prognostic model in MGMT unmethylated glioblastoma patients

  2025cites this paper
• Advances on the therapeutic potential of cell receptor activation in glioblastoma

  2025cites this paper
• Treatment practices and survival outcomes for IDH-wildtype glioblastoma patients according to MGMT promoter methylation status: insights from the U.S. National Cancer Database

  2025cites this paper
• Boswellia serrata for the Management of Radiation-Induced Cerebral Edema and Necrosis: A Systematic Meta-Narrative Review of Clinical Evidence

  2025cites this paper
• A New Systemic Disease Mouse Model for Glioblastoma Capable of Single-Tumour-Cell Detection

  2024cites this paper
• Angiogenesis inhibitors effects on overall survival and progression-free survival in newly diagnosed primary glioblastoma multiforme: a meta-analysis of twelve randomized clinical trials

  2024cites this paper
• Gene expression signature-defined necroinflammation is not associated with sex-biased survival or bevacizumab benefit in glioblastoma.

  2024cites this paper
• Efficacy and safety of bevacizumab combined with temozolomide in the treatment of glioma a systematic review and meta-analysis of clinical trials.

  2024cites this paper
• Stem the blood flow: beneficial impact of bevacizumab on survival of subventricular zone glioblastoma patients

  2024cites this paper
• Current chemotherapy strategies for adults with IDH-wildtype glioblastoma

  2024cites this paper
• Concurrent chemoradiation therapy for improving survival in older patients with glioblastoma: a narrative review

  2024cites this paper
• No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patients

  2024cites this paper
• Current status of precision oncology in adult glioblastoma

  2024influential citation
• Bevacizumab for Glioblastoma Multiforme: A Literature Review

  2024cites this paper
• Personalized prognosis stratification of newly diagnosed glioblastoma applying a statistical decision tree model

  2024cites this paper
• Glioblastoma Therapy: Past, Present and Future

  2024cites this paper
• Targeted Glioma Therapy—Clinical Trials and Future Directions

  2024cites this paper
• Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia

  2023cites this paper
• Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial

  2023cites this paper
• Initial Treatment of IDH-Wildtype Glioblastoma in Adults Older Than 70 Years

  2023cites this paper
• The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial

  2023cites this paper
• A scientometric analysis and up-to-date review of nano-based drug delivery systems in glioblastoma treatment

  2023cites this paper
• Bevacizumab is associated with cerebral microstructural alterations: a DTI study in high-grade glioma

  2023cites this paper
• Macrophages in Recurrent Glioblastoma as a Prognostic Factor in the Synergistic System of the Tumor Microenvironment

  2023cites this paper
• Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures

  2023cites this paper
• Efficacy and Safety of Bevacizumab for Treating Glioblastoma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials

  2023cites this paper
• Targeted therapies in patients with newly diagnosed glioblastoma—A systematic meta‐analysis of randomized clinical trials

  2023cites this paper
• Bevacizumab in real-life patients with recurrent glioblastoma: benefit or futility?

  2023cites this paper
• Prognostic differences and implications on treatment strategies between butterfly glioblastoma and glioblastoma with unilateral corpus callosum infiltration

  2022cites this paper
• The Next Frontier in Health Disparities—A Closer Look at Exploring Sex Differences in Glioma Data and Omics Analysis, from Bench to Bedside and Back

  2022cites this paper
• Quantitative Analysis of the MGMT Methylation Status of Glioblastomas in Light of the 2021 WHO Classification

  2022cites this paper
• Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS

  2022influential citation
• A Potential New Treatment for High-Grade Glioma: A Study Assessing Repurposed Drug Combinations against Patient-Derived High-Grade Glioma Cells

  2022cites this paper
• Anti-VEGFR2 monoclonal antibody(MSB0254) inhibits angiogenesis and tumor growth by blocking the signaling pathway mediated by VEGFR2 in glioblastoma.

  2022cites this paper
• Clinical strategies to manage adult glioblastoma patients without MGMT hypermethylation

  2022cites this paper
• Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline

  2021cites this paper
• Efficacy and safety of bevacizumab in the treatment of adult gliomas: a systematic review and meta-analysis

  2021cites this paper
• Emerging therapeutic targets for cerebral edema

  2021cites this paper
• Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy

  2021cites this paper
• Estimands for overall survival in clinical trials with treatment switching in oncology

  2021cites this paper
• Glioma stem cells and associated molecular mechanisms in Glioblastoma Chemoresistance

  2021cites this paper
• The Evolving Role of Targeted Therapies in Primary Central Nervous System Tumors

  2021cites this paper
• High-dose radiotherapy in newly diagnosed low-grade gliomas with nonmethylated O(6)-methylguanine-DNA methyltransferase

  2021cites this paper
• Fibroblast Activation Protein Expressing Mesenchymal Cells Promote Glioblastoma Angiogenesis

  2021cites this paper
• Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma

  2021cites this paper
• Advances in Chemokine Signaling Pathways as Therapeutic Targets in Glioblastoma

  2021influential citation
• Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 1 newly diagnosed disease

  2021cites this paper
• A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials

  2021cites this paper
• Gene expression-based biomarkers designating glioblastomas resistant to multiple treatment strategies

  2021cites this paper
• The Normal and Brain Tumor Vasculature: Morphological and Functional Characteristics and Therapeutic Targeting

  2021cites this paper
• Development of a Prodrug of Camptothecin for Enhanced Treatment of Glioblastoma Multiforme

  2021cites this paper
• Single-shot bevacizumab for cerebral radiation injury

  2021cites this paper
• Neurotoxicity of subarachnoid Gd-based contrast agent accumulation: a potential complication of intraoperative MRI?

  2021cites this paper
• Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma

  2020cites this paper
• Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting

  2020cites this paper
• Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors

  2020cites this paper
• Dissecting Molecular Features of Gliomas: Genetic Loci and Validated Biomarkers

  2020cites this paper
• Immunotherapy for Malignant Glioma: Current Status and Future Directions.

  2020cites this paper
• Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials

  2020cites this paper
• Endoplasmic Reticulum Stress and Autophagy in Cancer

  2020cites this paper
• HOX gene cluster (de)regulation in brain: from neurodevelopment to malignant glial tumours

  2020cites this paper
• Glioblastoma multiforme: novel therapeutic targets

  2020cites this paper
• The quality of measurement properties of neurocognitive assessment in brain tumor clinical trials over the last 30 years: a COSMIN checklist-based approach

  2020cites this paper
• Rehabilitation of Adult Patients with Primary Brain Tumors: A Narrative Review

  2020cites this paper
• Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme.

  2020cites this paper
• Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma.

  2020cites this paper
• Randomized controlled trials—a critical re-appraisal

  2020cites this paper
• Optimal treatment strategy for adult patients with newly diagnosed glioblastoma: a systematic review and network meta-analysis

  2020cites this paper
• Low mitochondrial DNA copy number is associated with poor prognosis and treatment resistance in glioblastoma.

  2020cites this paper
• Increased epithelial membrane protein 2 expression in glioblastoma after treatment with bevacizumab

  2020cites this paper
• MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA‐09 trial

  2020cites this paper
• HEMATOTOXIC ADVERSE DRUG REACTIONS ASSOCIATED WITH VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS AND CYTOTOXIC DRUGS IN THE TREATMENT OF GLIOBLASTOMA: A SYSTEMATIC REVIEW

  2020cites this paper
• Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma

  2020cites this paper
• Chemotherapy for Brain Tumors

  2020cites this paper
• Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.

  2020cites this paper
• Adjuvant therapy and molecular profiling for inoperable gliomas

  2019cites this paper
• Gliome

  2019cites this paper
• Molecular targeted therapy of glioblastoma.

  2019cites this paper
• Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma

  2019cites this paper
• Newly Diagnosed Glioblastoma: A Review on Clinical Management.

  2019cites this paper
• Design, Synthesis, and Biological Evaluation of Novel Allosteric Protein Disulfide Isomerase Inhibitors.

  2019cites this paper
• Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.

  2019cites this paper
• Improving survival in molecularly selected glioblastoma.

  2019cites this paper
• Current clinical management of patients with glioblastoma

  2019influential citation
• Adrenal Insufficiency in Patients with Corticosteroid-Refractory Cerebral Radiation Necrosis Treated with Bevacizumab

  2019cites this paper